Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on January 3, 2005, covering events occurring on December 31, 2004, and November 30, 2004. The filing details unregistered sales of equity securities pursuant to Item 3.02.
Key Financial Metrics and Transactions
- Merck Milestone Payment: On December 31, 2004, Alnylam issued 710,273 shares of common stock to Merck & Co., Inc. for an aggregate purchase price of $5,000,000. This transaction was triggered by the achievement of a milestone under a Research Collaboration and License Agreement entered into in September 2003.
- Warrant Exercise: On November 30, 2004, Alnylam issued 5,345 shares of common stock to Silicon Valley Bank. This resulted from a cashless exercise of a warrant at an exercise price of $4.75 per share, where 7,812 originally issuable shares were cancelled to cover the purchase price.
- Liquidity and Debt: The filing text does not provide clear values for overall revenue, profit, cash flow, margins, or total debt levels.
Material Changes
The primary material change reported is the issuance of equity securities to fund a research milestone and satisfy a warrant obligation. The filing does not provide comparative financial data against prior periods to quantify changes in revenue or profitability.
Guidance, Risks, and Unusual Items
- Regulatory Exemptions: Both transactions were conducted in reliance on exemptions from registration under Section 4(2) and/or Regulation D of the Securities Act of 1933, as they did not involve a public offering.
- Investor Status: Both purchasers (Merck and Silicon Valley Bank) represented themselves as accredited investors acquiring shares for investment purposes only, not for distribution.
- Outlook: The filing contains no forward-looking guidance or management commentary regarding future financial performance.
Key Facts for Investor Verification
- Verify the specific milestone achieved under the September 2003 agreement with Merck that triggered the $5,000,000 payment.
- Confirm the total number of outstanding shares post-transaction to assess the dilution impact of the 715,618 total shares issued in these two events.
- Review the full terms of the Research Collaboration and License Agreement with Merck to understand future payment obligations.
- Check subsequent filings for the company's cash position following these equity issuances, as this 8-K does not report a balance sheet.